Is Spyre Therapeutics (NASDAQ:SYRE) Slipping 8.71% After a Wider Third Quarter Loss?

Vinay Lochav

04 November 2026 11:32 PM AEDT

Is Spyre Therapeutics (NASDAQ:SYRE) Slipping 8.71% After a Wider Third Quarter Loss?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Shares dropped 8.71% to USD 90.62 in premarket trading on November 4, 2026, a fall of USD 8.65.
The third quarter net loss came to USD 96.1 million, or USD 0.94 per share, compared with USD 11.2 million a year earlier.
Pro forma cash stood at USD 1,467.9 million, including financing completed in October 2026, with runway expected into the second half of 2029.
Research and development spending climbed to USD 89.2 million from USD 45.2 million.
Randomized induction data for the ulcerative colitis program are anticipated in the third quarter of 2027.

What Drove Spyre Therapeutics Lower Before the Open (down USD 8.65, 8.71%)

Spyre Therapeutics (NASDAQ:SYRE) traded 8.71% lower at USD 90.62 in premarket trading on November 4, 2026, a decline of USD 8.65 from an implied Tuesday, November 3, 2026 close of about USD 99.27 (calculated from the screen figures).

The company released its third quarter 2026 results and corporate update on November 3, 2026, and the selloff appears to reflect a much wider quarterly loss, though no single cause has been confirmed.

The Third Quarter Results Explained

Per the company press release, the net loss for the three months ended September 30, 2026 totaled USD 96.1 million, up from USD 11.2 million in the same quarter of 2025. Loss per share was USD 0.94 versus USD 0.15. Research and Development spending reached USD 89.2 million, compared with USD 45.2 million, reflecting Manufacturing and clinical trial costs, while general and administrative expense increased to USD 16.6 million from USD 11.6 million.

Other income declined to USD 9.6 million from USD 45.7 million. Net cash used in operations amounted to USD 77.5 million. Over the nine months, the net loss reached USD 201.3 million, or USD 2.04 per share, up from USD 92.7 million a year earlier.

The company also said that all three monotherapies in Part A of its Phase 2 SKYLINE ulcerative colitis study met their primary endpoints. The Robarts Histopathology index fell by 9.2 points for SPY001, 10.7 points for SPY002 and 10.0 points for SPY003.

Business Background and Pipeline Updates

Spyre is a clinical-stage biotechnology company that develops antibody therapies for inflammatory bowel disease and other immune conditions. Its candidates target alpha4beta7, TL1A and IL-23.

Clinical remission at Week 12 in Part A reached 40% for SPY001, 33% for SPY002 and 20% for SPY003. Part B is randomized and placebo controlled, with induction data expected in the third quarter of 2027, and enrollment is running ahead of schedule. Combination arms SPY120, SPY130 and SPY230 are currently enrolling.

Results for SPY072 in rheumatic disease were mixed. The psoriatic arthritis and axial spondyloarthritis studies failed to meet their primary endpoints. The company will not advance SPY072 in rheumatic diseases and started a Phase 2 hidradenitis suppurativa study in September 2026.

Balance Sheet and Risks

Cash, cash equivalents and marketable securities totaled USD 1,071.9 million at September 30, 2026. The pro forma figure of USD 1,467.9 million adds an October underwritten offering with net proceeds of USD 378.0 million and USD 18.0 million raised through at-the-market sales.

Common shares outstanding were 89,953,997 at September 30, 2026, up from 78,189,811 at the end of 2025. The October financing adds more shares, though the release does not quantify them. Clinical-stage companies face trial, regulatory and dilution risk, and valuations can swing sharply on data.

What to Watch Next

Track enrollment progress in SKYLINE Part B and the third quarter 2027 induction readout. Week 16 data from the hidradenitis suppurativa proof-of-concept study are due in late 2027 or early 2028, and pivotal monotherapy studies in that disease are planned for 2027.

FAQs

Q: Why is the stock lower in premarket trading on November 4, 2026?

A: The shares fell 8.71% to USD 90.62 after third quarter results released on November 3, 2026 showed a net loss of USD 96.1 million. The company has not given a reason for the move.

Q: How much cash does the company have?

A: Cash, equivalents and marketable securities were USD 1,071.9 million at September 30, 2026, and pro forma cash was USD 1,467.9 million including October financing. The company expects its runway to extend into the second half of 2029.

Q: When is the next major clinical readout?

A: Randomized induction data from Part B of the SKYLINE ulcerative colitis study are expected in the third quarter of 2027.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.